COVID-19
Conditions
Brief summary
180 people from the medical staff and high-risk people in Baqiyatallah Hospital, who are in close contact with patients, will enter the study. Participants will be divided into two intervention groups and one control group. The control group will use the full protective equipment assigned to the treatment staff. In addition to protective equipment, the first intervention team will receive a daily diet of 200 mg hydroxychloroquine tablets. The second intervention team, while observing and using the complete protective equipment, will place a thin layer of Mucodentol gel in the vestibular area of the mouth daily, every 6 to 8 hours. At the beginning of the treatment, qualified people will participate in the study while recording demographic and clinical information, PCR test will be performed, and if they have negative PCR, they will be in one of the 3 study groups. During the study, if the symptoms of the disease occur in each of the participants, the test will be taken again. If the test is positive, the person will withdraw from the study, and the patient's information will be recorded. Finally, the people present in the study will be tested for PCR, and the results of the disease and the side effects of the drugs will be compared.
Interventions
DRUGHydroxychloroquine
200 mg of hydroxychloroquine daily for participants in the intervention group 1
DRUGMucodentol
Intervention Group 2 participants will place a thin layer of Dentol gel in the vestibular area of the mouth every 6 to 8 hours.
DEVICEPersonal protective equipment
Personal protective equipment such as masks, gloves, protective shields
Sponsors
Baqiyatallah Medical Sciences University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Negative PCR testing through throat swabs * Signing Conscious Consent
Exclusion criteria
* History of ocular complications and visual disturbances * Sensitivity to plant compounds in the product
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PCR test | up to 1 month | Laboratory PCR testing can help diagnose the disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory Treatment Response | up to 1 month | Normal blood cell count and CRP count (normal laboratory range) |
| drug reactions Adverse | up to 1 month | Complications in both groups should be evaluated and evaluated during treatment. |
| Allergic drug | up to 1 month | There will be known allergic reactions to the drugs. |
| Radiological Treatment Response | up to 1 month | CT scans help determine how much the lungs are affected by COVID-19. |
Countries
Iran
Outcome results
None listed